Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
Saved in:
| Published in: | Lung Cancer: Targets and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2025
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301673277325315 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Lung Cancer: Targets and Therapy |
| description | |
| discipline_display | Respiratory Diseases |
| discipline_facet | Respiratory Diseases |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:58418 |
| institution | FRELIP |
| journal_source_facet | Lung Cancer: Targets and Therapy |
| publishDate | 2025 |
| publishDateSort | 2025 |
| record_format | rss_article |
| spellingShingle | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 Respiratory Diseases General Respiratory Diseases |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Respiratory Diseases General Respiratory Diseases Respiratory Diseases General Respiratory Diseases |
| subject_facet | Respiratory Diseases General Respiratory Diseases |
| title | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_auth | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_full | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_fullStr | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_full_unstemmed | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_short | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_sort | a concise review of the approved met tkis (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) in china for met exon 14 splice site mutated (metex14+) nsclc circa 2025 |
| topic | Respiratory Diseases General Respiratory Diseases |
| url | https://www.dovepress.com/a-concise-review-of-the-approved-met-tkis-savolitinib-gumarontinib-veb-peer-reviewed-fulltext-article-LCTT |